Nasdaq-listed Sonnet BioTherapeutics agrees to $888 million merger to become Hyperliquid Strategies, launch HYPE treasury
18 hours ago
Nasdaq-listed Sonnet BioTherapeutics, Inc. has agreed to merge with Rorschach I LLC to become Hyperliquid Strategies, Inc. and launch a HYPE treasury …